Makhani N, Morrow S A, Fisk J, Evans C, Beland S G, Kulaga S, Kingwell E, Marriott J J, Dykeman J, Jetté N, Pringsheim T, Wolfson C, Marrie R A, Koch M W
Department of Pediatrics, Division of Neurology, The Hospital for Sick Children, Toronto, Canada; Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, Canada.
Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada.
Mult Scler Relat Disord. 2014 Jan;3(1):48-60. doi: 10.1016/j.msard.2013.06.015. Epub 2013 Jul 25.
Studies of multiple sclerosis (MS) incidence and prevalence from Africa, Asia, Australia and New Zealand are relatively scarce. We systematically reviewed MS incidence and prevalence in these regions including a standardized evaluation of study quality.
We searched MEDLINE and EMBASE databases for studies of MS prevalence or incidence in Africa, Asia, Australia and New Zealand published in English or French between January 1, 1985 and January 31, 2011. Study quality was assessed using a standardized tool. All steps of the review were performed in duplicate.
Of 3925 citations identified, 28 studies met inclusion criteria and 21 of these were from Asia. Quality scores ranged from 1/8 to 8/8; the lowest scores were observed in studies from Asia (median 4/8, IQR 3,6). Prevalence was lowest in South African Blacks (0.22/100,000) and highest amongst Australian-born individuals in Australia (125/100,000). Prevalence increased over time in many countries. MS prevalence increased with increasing latitude only in some regions, and prevalence varied significantly with ethnicity. Eight studies reported incidence, which ranged from 0.67/100,000/year in Taiwan to 3.67/100,00/year in Australia.
This comprehensive study provides an update of MS epidemiology in Africa, Asia, Australia, and New Zealand. Incidence and prevalence were lowest in Africa and Asia and highest in Australia, but many Asian studies were of poor quality. Use of consistent case ascertainment methods, standardized data collection tools, and similar outcomes would all improve study quality and comparability. The underlying basis of observed ethnic differences is an important area for future study.
来自非洲、亚洲、澳大利亚和新西兰的多发性硬化症(MS)发病率和患病率研究相对较少。我们系统回顾了这些地区的MS发病率和患病率,包括对研究质量的标准化评估。
我们检索了MEDLINE和EMBASE数据库,以查找1985年1月1日至2011年1月31日期间以英文或法文发表的关于非洲、亚洲、澳大利亚和新西兰MS患病率或发病率的研究。使用标准化工具评估研究质量。综述的所有步骤均重复进行。
在识别出的3925条引文中,28项研究符合纳入标准,其中21项来自亚洲。质量得分范围为1/8至8/8;亚洲的研究得分最低(中位数4/8,四分位间距3,6)。南非黑人的患病率最低(0.22/100,000),而澳大利亚出生的澳大利亚人患病率最高(125/100,000)。许多国家的患病率随时间增加。仅在某些地区,MS患病率随纬度增加而增加,且患病率因种族而异。八项研究报告了发病率,范围从台湾的0.67/100,000/年到澳大利亚的3.67/100,00/年。
这项全面的研究提供了非洲、亚洲、澳大利亚和新西兰MS流行病学的最新情况。非洲和亚洲的发病率和患病率最低,澳大利亚最高,但许多亚洲研究质量较差。使用一致的病例确诊方法、标准化的数据收集工具和相似的结果将提高研究质量和可比性。观察到的种族差异的潜在基础是未来研究的一个重要领域。